ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

176Citations
Citations of this article
166Readers
Mendeley users who have this article in their library.

Abstract

It was only 3 years ago that an acquired translocation of EML4 with ALK leading to the expression of an EML4-ALK oncoprotein in non-small cell lung cancer (NSCLC) was reported. Tumor cells expressing EML4-ALK are "addicted" to its continued function. Now, crizotinib, an oral ALK inhibitor, is demonstrated to provide dramatic clinical benefit with little toxicity in patients having such advanced NSCLC, and a mechanism of clinical resistance to crizotinib is identified. Such therapy "targeted" at oncogenic proteins provides "personalized" medicine and prompts genome-wide mutation analysis of human tumors to find other therapeutic targets. © 2010 Elsevier Inc.

Cite

CITATION STYLE

APA

Gerber, D. E., & Minna, J. D. (2010, December 14). ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time. Cancer Cell. https://doi.org/10.1016/j.ccr.2010.11.033

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free